2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
18
Lymphoma, Non-Hodgkin
7
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, B-Cell
5
Waldenstrom Macroglobulinemia
3
Recurrence
3
Lymphoma
2
Optic Neuritis
1
Neuromyelitis Optica
1
Myelitis, Transverse
1
Lymphoma, Large B-Cell, Diffuse
1
Disease Progression
1
Interventions
Rituximab
416
Cyclophosphamide
348
Vincristine
173
Prednisone
172
Doxorubicin
168
Etoposide
160
Peripheral Blood Stem Cell Transplantation
114
Filgrastim
108
Lenalidomide
97
fludarabine phosphate
96
Radiotherapy
80
Cytarabine
80
Gemcitabine
73
Melphalan
66
Mycophenolic Acid
64
Cyclosporine
60
Methotrexate
59
Busulfan
57
Ifosfamide
55
Carmustine
55
fludarabine
50
Tacrolimus
50
Whole-Body Irradiation
49
Carboplatin
49
polatuzumab vedotin
44
Oxaliplatin
44
Dexamethasone
44
Antilymphocyte Serum
42
ibrutinib
40
Bendamustine Hydrochloride
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
ublituximab
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA